Abstract
In this report we will provide additional insight on the individual features of age-related causes of mobility limitation, explaining why insulin resistance, related to lower muscle functioning, sub-inflammation and hormonal changes, may contribute to its onset and sustain it. According to the recent literature, the same factors playing a role in the onset and maintenance of insulin resistance are related to mobility limitation. Thus, the presence of insulin resistance can be considered a biomarker of susceptibility to mobility limitation among older persons. All described factors related to both conditions are strictly intertwined. Therefore, the identification and correction of a single factor is difficult to convert into clinical practice. Instead, insulin resistance may be considered not only an early biological marker, but also a predictive and modifiable marker of mobility limitation. Thus, interventions aimed at correcting insulin resistance may have a potential role in preventing or at least slowing down functional decline in the elderly population, promoting a better quality of life and potentially extending the “healthspan”.
Keywords: Insulin resistance, mobility limitation, older persons.
Current Pharmaceutical Design
Title:The Link between Insulin Resistance and Mobility Limitation in Older Persons
Volume: 20 Issue: 19
Author(s): Virginia Boccardi and Giuseppe Paolisso
Affiliation:
Keywords: Insulin resistance, mobility limitation, older persons.
Abstract: In this report we will provide additional insight on the individual features of age-related causes of mobility limitation, explaining why insulin resistance, related to lower muscle functioning, sub-inflammation and hormonal changes, may contribute to its onset and sustain it. According to the recent literature, the same factors playing a role in the onset and maintenance of insulin resistance are related to mobility limitation. Thus, the presence of insulin resistance can be considered a biomarker of susceptibility to mobility limitation among older persons. All described factors related to both conditions are strictly intertwined. Therefore, the identification and correction of a single factor is difficult to convert into clinical practice. Instead, insulin resistance may be considered not only an early biological marker, but also a predictive and modifiable marker of mobility limitation. Thus, interventions aimed at correcting insulin resistance may have a potential role in preventing or at least slowing down functional decline in the elderly population, promoting a better quality of life and potentially extending the “healthspan”.
Export Options
About this article
Cite this article as:
Boccardi Virginia and Paolisso Giuseppe, The Link between Insulin Resistance and Mobility Limitation in Older Persons, Current Pharmaceutical Design 2014; 20 (19) . https://dx.doi.org/10.2174/13816128113196660683
DOI https://dx.doi.org/10.2174/13816128113196660683 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Getting to Know the Cast - Cellular Interactions and Signaling at the Neurovascular Unit
Current Pharmaceutical Design Biology and Regulatory Roles of Nuclear Lamins in Cellular Function and Dysfunction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Statins and Solid Organ Transplantation
Current Pharmaceutical Design Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme
Current Clinical Pharmacology Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Anti-Proliferative Activity of Standardized Methanol Extract of Coscinium fenestratum and Its Major Constituent, Berberine, Against Nasopharyngeal Carcinoma Cells
The Natural Products Journal Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: New Developments in the Treatment and Prevention of Vascular Disease - Part 1 (Executive Editors: N. Katsiki, V.G. Athyros and D.P. Mikhailidis)]
Current Pharmaceutical Design The PD-1/PD-L1 Pathway in Human Pathology
Current Molecular Medicine Proteomic Profiling of Maternal Serum for Early Risk Analysis of Preterm Birth
Current Proteomics Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Current Molecular Medicine Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Non-Insulin Dependent Diabetes Mellitus: Present Therapies and New Drug Targets&#
Mini-Reviews in Medicinal Chemistry Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
Current Drug Targets - Infectious Disorders Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity
Mini-Reviews in Medicinal Chemistry The Dynamics of Drug Discovery
Current Topics in Medicinal Chemistry Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets